Oncostatin M Reduces Lesion Size and Promotes Functional Recovery and Neurite Outgrowth After Spinal Cord Injury

Molecular Neurobiology

Volumn 50, Issue 3, 2014, Pages 1142-1151

  Slaets, Helena ^a   Nelissen, Sofie ^a,b   Janssens, Kris ^a   Vidal, Pia M ^a   Lemmens, Evi ^a   Stinissen, Piet ^a   Hendrix, Sven ^a   Hellings, Niels ^a  

^a HASSELT UNIVERSITY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Neuroinflammation; Neuroprotection; OSM; SCI

Indexed keywords

NEUROPROTECTIVE AGENT; ONCOSTATIN M;

ANIMAL; CONVALESCENCE; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOUSE; NEURITE; PATHOPHYSIOLOGY; PHYSIOLOGY; SPINAL CORD INJURIES; UPREGULATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; NEURITES; NEUROPROTECTIVE AGENTS; ONCOSTATIN M; RECOVERY OF FUNCTION; SPINAL CORD INJURIES; UP-REGULATION;

EID: 84922146583     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8795-5     Document Type: Article

References (42)

1. Kopp MA, Druschel C, Meisel C, Liebscher T, Prilipp E, Watzlawick R, Cinelli P, Niedeggen A, Schaser KD, Wanner GA, Curt A, Lindemann G, Nugaeva N, Fehlings MG, Vajkoczy P, Cabraja M, Dengler J, Ertel W, Ekkernkamp A, Martus P, Volk HD, Unterwalder N, Kolsch U, Brommer B, Hellmann RC, Ossami Saidi RR, Laginha I, Pruss H, Failli V, Dirnagl U, Schwab JM (2013) The SCIentinel study—prospective multicenter study to define the spinal cord injury-induced immune depression syndrome (SCI-IDS) - study protocol and interim feasibility data. BMC Neurol 13(1):168. doi:10.1186/1471-2377-13-168
2. Donnelly DJ, Popovich PG (2008) Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 209(2):378–388. doi:10.1016/j.expneurol.2007.06.009
3. Vidal PM, Lemmens E, Dooley D, Hendrix S (2013) The role of “anti-inflammatory” cytokines in axon regeneration. Cytokine Growth Factor Rev 24(1):1–12. doi:10.1016/j.cytogfr.2012.08.008
4. Gupta R, Bathen ME, Smith JS, Levi AD, Bhatia NN, Steward O (2010) Advances in the management of spinal cord injury. J Am Acad Orthop Surg 18(4):210–222
5. Dooley D, Vidal P, Hendrix S (2013) Immunopharmacological intervention for successful neural stem cell therapy: New perspectives in CNS neurogenesis and repair. Pharmacol Ther. doi:10.1016/j.pharmthera.2013.08.001
6. Slaets H, Hendriks JJ, Stinissen P, Kilpatrick TJ, Hellings N (2010) Therapeutic potential of LIF in multiple sclerosis. Trends Mol Med 16(11):493–500. doi:10.1016/j.molmed.2010.08.007
7. Lacroix S, Chang L, Rose-John S, Tuszynski MH (2002) Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol 454(3):213–228. doi:10.1002/cne.10407
8. Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, Robben J, Hendriks J, Stinissen P, Hellings N (2008) Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 8(6):1237–1247. doi:10.1002/pmic.200700641
9. Kerr BJ, Patterson PH (2005) Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 51(1):73–79. doi:10.1002/glia.20177
10. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, Martinez T, Drummond J, Dike S, Pletnikov M, Keswani SC, Moran TH, Pardo CA, Calabresi PA, Kerr DA (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115(10):2731–2741. doi:10.1172/JCI25141
11. Fearon U, Mullan R, Markham T, Connolly M, Sullivan S, Poole AR, FitzGerald O, Bresnihan B, Veale DJ (2006) Oncostatin M induces angiogenesis and cartilage degradation in rheumatoid arthritis synovial tissue and human cartilage cocultures. Arthritis Rheum 54(10):3152–3162. doi:10.1002/art.22161
12. Botelho FM, Rangel-Moreno J, Fritz D, Randall TD, Xing Z, Richards CD (2013) Pulmonary expression of oncostatin M (OSM) promotes inducible BALT formation independently of IL-6, despite a role for IL-6 in OSM-driven pulmonary inflammation. J Immunol 191(3):1453–1464. doi:10.4049/jimmunol.1203318
13. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E, Garcia M, Venereau E, Preisser L, Guignouard E, Guillet G, Dagregorio G, Pene J, Moles JP, Yssel H, Chevalier S, Bernard FX, Gascan H, Lecron JC (2007) Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 178(7):4615–4622
14. Giot JP, Paris I, Levillain P, Huguier V, Charreau S, Delwail A, Garcia M, Garnier J, Bernard FX, Dagregorio G, Guillet G, Morel F, Lecron JC, Favot L (2013) Involvement of IL-1 and oncostatin M in acanthosis associated with hypertensive leg ulcer. Am J Pathol 182(3):806–818. doi:10.1016/j.ajpath.2012.11.030
15. Ensoli F, Fiorelli V, DeCristofaro M, Santini Muratori D, Novi A, Vannelli B, Thiele CJ, Luzi G, Aiuti F (1999) Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons. J Immunol 162(10):6268–6277
16. Nelissen S, Vangansewinkel T, Geurts N, Geboes L, Lemmens E, Vidal PM, Lemmens S, Willems L, Boato F, Dooley D, Pehl D, Pejler G, Maurer M, Metz M, Hendrix S (2013) Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. Neurobiol Dis 62C:260–272. doi:10.1016/j.nbd.2013.09.012
17. Ruprecht K, Kuhlmann T, Seif F, Hummel V, Kruse N, Bruck W, Rieckmann P (2001) Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions. J Neuropathol Exp Neurol 60(11):1087–1098
18. Jankowsky JL, Patterson PH (1999) Differential regulation of cytokine expression following pilocarpine-induced seizure. Exp Neurol 159(2):333–346. doi:10.1006/exnr.1999.7137
19. Cho N, Nguyen DH, Satkunendrarajah K, Branch DR, Fehlings MG (2012) Evaluating the role of IL-11, a novel cytokine in the IL-6 family, in a mouse model of spinal cord injury. J Neuroinflammation 9:134. doi:10.1186/1742-2094-9-134
20. Guerrero AR, Uchida K, Nakajima H, Watanabe S, Nakamura M, Johnson WE, Baba H (2012) Blockade of interleukin-6 signaling inhibits the classic pathway and promotes an alternative pathway of macrophage activation after spinal cord injury in mice. J Neuroinflammation 9:40. doi:10.1186/1742-2094-9-40
21. Mukaino M, Nakamura M, Yamada O, Okada S, Morikawa S, Renault-Mihara F, Iwanami A, Ikegami T, Ohsugi Y, Tsuji O, Katoh H, Matsuzaki Y, Toyama Y, Liu M, Okano H (2010) Anti-IL-6-receptor antibody promotes repair of spinal cord injury by inducing microglia-dominant inflammation. Exp Neurol 224(2):403–414. doi:10.1016/j.expneurol.2010.04.020
22. Cafferty WB, Gardiner NJ, Das P, Qiu J, McMahon SB, Thompson SW (2004) Conditioning injury-induced spinal axon regeneration fails in interleukin-6 knock-out mice. J Neurosci Off J Soc Neurosci 24(18):4432–4443. doi:10.1523/JNEUROSCI.2245-02.2004
23. Kerr BJ, Patterson PH (2004) Potent pro-inflammatory actions of leukemia inhibitory factor in the spinal cord of the adult mouse. Exp Neurol 188(2):391–407. doi:10.1016/j.expneurol.2004.04.012
24. Weiss TW, Samson AL, Niego B, Daniel PB, Medcalf RL (2006) Oncostatin M is a neuroprotective cytokine that inhibits excitotoxic injury in vitro and in vivo. FASEB J Off Publ Fed Am Soc Exp Biol 20(13):2369–2371. doi:10.1096/fj.06-5850fje
25. Xia X, Li Y, Huang D, Wang Z, Luo L, Song Y, Zhao L, Wen R (2011) Oncostatin M protects rod and cone photoreceptors and promotes regeneration of cone outer segment in a rat model of retinal degeneration. PLoS One 6(3):e18282. doi:10.1371/journal.pone.0018282
26. Moidunny S, Dias RB, Wesseling E, Sekino Y, Boddeke HW, Sebastiao AM, Biber K (2010) Interleukin-6-type cytokines in neuroprotection and neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires neuronal adenosine A1 receptor function. J Neurochem 114(6):1667–1677. doi:10.1111/j.1471-4159.2010.06881.x
27. Baker BJ, Park KW, Qin H, Ma X, Benveniste EN (2010) IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. Glia 58(9):1082–1093. doi:10.1002/glia.20989
28. Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y (2013) Lack of oncostatin M receptor beta leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J Biol Chem 288(30):21861–21875. doi:10.1074/jbc.M113.461905
29. Korzus E, Nagase H, Rydell R, Travis J (1997) The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem 272(2):1188–1196
30. Repovic P, Mi K, Benveniste EN (2003) Oncostatin M enhances the expression of prostaglandin E2 and cyclooxygenase-2 in astrocytes: synergy with interleukin-1beta, tumor necrosis factor-alpha, and bacterial lipopolysaccharide. Glia 42(4):433–446. doi:10.1002/glia.10182
31. Ganesh K, Das A, Dickerson R, Khanna S, Parinandi NL, Gordillo GM, Sen CK, Roy S (2012) Prostaglandin E2 Induces Oncostatin M Expression in Human Chronic Wound Macrophages through Axl Receptor Tyrosine Kinase Pathway. J Immunol. doi:10.4049/jimmunol.1102762
32. Metcalfe SM (2011) LIF in the regulation of T-cell fate and as a potential therapeutic. Genes Immun 12(3):157–168. doi:10.1038/gene.2011.9
33. Walsh JT, Kipnis J (2011) Regulatory T cells in CNS injury: the simple, the complex and the confused. Trends Mol Med 17(10):541–547. doi:10.1016/j.molmed.2011.05.012
34. Glezer I, Rivest S (2010) Oncostatin M is a novel glucocorticoid-dependent neuroinflammatory factor that enhances oligodendrocyte precursor cell activity in demyelinated sites. Brain Behav Immun 24(5):695–704. doi:10.1016/j.bbi.2010.01.005
35. Vidal PM, Lemmens E, Avila A, Vangansewinkel T, Chalaris A, Rose-John S, Hendrix S (2013) ADAM17 is a survival factor for microglial cells in vitro and in vivo after spinal cord injury in mice. Cell Death Dis 4:e954. doi:10.1038/cddis.2013.466
36. Boato F, Hendrix S, Huelsenbeck SC, Hofmann F, Grosse G, Djalali S, Klimaschewski L, Auer M, Just I, Ahnert-Hilger G, Holtje M (2010) C3 peptide enhances recovery from spinal cord injury by improved regenerative growth of descending fiber tracts. J Cell Sci 123(Pt 10):1652–1662. doi:10.1242/jcs.066050
37. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG (2006) Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 23(5):635–659. doi:10.1089/neu.2006.23.635
38. Sheng H, Wang H, Homi HM, Spasojevic I, Batinic-Haberle I, Pearlstein RD, Warner DS (2004) A no-laminectomy spinal cord compression injury model in mice. J Neurotrauma 21(5):595–603. doi:10.1089/089771504774129928
39. Beck KD, Nguyen HX, Galvan MD, Salazar DL, Woodruff TM, Anderson AJ (2010) Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain J Neurol 133(Pt 2):433–447. doi:10.1093/brain/awp322
40. Boato F, Rosenberger K, Nelissen S, Geboes L, Peters EM, Nitsch R, Hendrix S (2013) Absence of IL-1beta positively affects neurological outcome, lesion development and axonal plasticity after spinal cord injury. J Neuroinflammation 10:6. doi:10.1186/1742-2094-10-6
41. Holtje M, Djalali S, Hofmann F, Munster-Wandowski A, Hendrix S, Boato F, Dreger SC, Grosse G, Henneberger C, Grantyn R, Just I, Ahnert-Hilger G (2009) A 29-amino acid fragment of Clostridium botulinum C3 protein enhances neuronal outgrowth, connectivity, and reinnervation. FASEB J Off Publ Fed Am Soc Exp Biol 23(4):1115–1126. doi:10.1096/fj.08-116855
42. Boato F, Hechler D, Rosenberger K, Ludecke D, Peters EM, Nitsch R, Hendrix S (2011) Interleukin-1 beta and neurotrophin-3 synergistically promote neurite growth in vitro. J Neuroinflammation 8:183. doi:10.1186/1742-2094-8-183